0.3% benzydamine hydrochloride spray oromucosal solution; Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)
Phase IV Study Comparing the Efficacy and Safety of Benzydamine Hydrochloride 0,3% Oromucosal Spray and Benzydamine Hydrochloride 3 mg Lozenges in Patients With Acute Sore Throat
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04941976/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 356 чел. во всех странах исследования.
- Центров в реестре: 6 в одном городе. Список — ниже на странице.
- Плановая дата окончания (06.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 15
Критерии включения
- Adult male and female patients (aged 18 - 75 years, limits included) with recent onset (≤3 days) of sore throat and a diagnosis of tonsillopharyngitis confirmed by:
- Presence of at least one symptom of URTI in the previous 24 h on the URTI questionnaire;
- Sore throat pain intensity score ≥ 60 mm on Sore Throat Pain Intensity Scale (STPIS);
- A score ≥ 5 on Tonsillo-Pharingytis Assessment (TPA);
- Women of childbearing potential or with no menses for a period < 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the Visit 2, using an appropriate birth control method such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered:
- Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
- Patients legally capable of giving their consent to participate in the study (including personal data processing) and available to sign and date the written informed consent.
Критерии невключения
- Known hypersensitivity to benzydamine or its excipients;
- Phenylketonuria;
- Clinically significant abnormalities at physical examination and vital signs;
- Intolerance to acetylsalicylic acid or other NSAIDS;
- History or diagnosis of asthma;
- Any concomitant disease that compromise breathing (i.e. bronchopneumonia);
- Mouth breathing due to nasal congestion which causes throat drying;
- Severe coughing which causes throat discomfort;
- Purulent plaques on the tonsils;
- Any inhaled therapy in the previous week before the first drug administration;
- Use of antibiotics for an acute disease in the 7 days before randomisation (chronic antibiotic use, such as for acne, is acceptable); any sustained release analgesic within 24 hours of administration of study medication; any medications for cold and flu (i.e., decongestants, antihistamines, expectorants, antitussives), immediate release analgesic or antipyretic within 4 hours of administration of study medication;
- Use of any lozenge, mouthwash, spray or menthol-containing products within 2 hours of administration of study medication;
- Women during pregnancy or lactation period;
- Subject involved in the conduct of the study (e.g. Investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel, etc);
- Participation to a clinical trial within 3 months prior to the inclusion in the study.
Источник: ClinicalTrials.gov, NCT04941976 · запись обновлена в реестре 22 июля 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 4
- Percentage of responders at 2 min — 2 minutes
Цель исследования
The aim of this study is to generate new clinical data about the speed of relief provided by a single application of Benzydamine hydrochloride 0,3% oromucosal spray vs Benzydamine hydrochloride 3 mg lozenges mint flavour.
Где проходит
6 центров в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04941976 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.